SCHEMBL1017472

SCHEMBL1017472

Cc1nc(NCc2ccccc2F)ncc1C(=O)NC1CCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYRO3 Q06418 11/20 0.55
SELP P16109 5/20 0.55
CHEK1 O14757 2/20 0.55
IKBKB O14920 2/20 0.55
AURKA O14965 2/20 0.55
PAK4 O96013 2/20 0.55
CHEK2 O96017 2/20 0.55
ABL1 P00519 2/20 0.55
EGFR P00533 2/20 0.55
INSR P06213 2/20 0.55
LCK P06239 2/20 0.55
FGFR1 P11362 2/20 0.55
CSNK2A2 P19784 2/20 0.55
CCNA2 P20248 2/20 0.55
CDK2 P24941 2/20 0.55
MAPK1 P28482 2/20 0.55
AKT1 P31749 2/20 0.55
CSNK1D P48730 2/20 0.55
MAPKAPK2 P49137 2/20 0.55
GSK3B P49841 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014721 0.99 TYRO3 (0.54) TYRO3SELPCHEK1IKBKBAURKA
SCHEMBL1015098 0.86 TYRO3 (0.70) TYRO3SELPCHEK1IKBKBAURKA
SCHEMBL1016069 0.85 TYRO3 (0.69) TYRO3SELPCHEK1IKBKBAURKA
SCHEMBL1013869 0.85 RAB9A (0.60) TYRO3SELPCHEK1IKBKBAURKA
SCHEMBL1015403 0.84 RAB9A (0.58) TYRO3SELPCHEK1IKBKBAURKA
SCHEMBL1014913 0.84 RAB9A (0.58) TYRO3SELPCHEK1IKBKBAURKA
SCHEMBL1012283 0.77 TYRO3 (0.54) TYRO3SELPCHEK1IKBKBAURKA
SCHEMBL1013775 0.76 NPC1 (0.55) TYRO3SELPCHEK1IKBKBAURKA
SCHEMBL1015199 0.76 NPC1 (0.55) TYRO3SELPCHEK1IKBKBAURKA
SCHEMBL1015261 0.76 TYRO3 (0.54) TYRO3SELPCHEK1IKBKBAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102066335-A Substituted pyrimidin-5-carboxamides 281 ASTRAZENECA AB 2011-05-18 CN disclosed
EP-2271629-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 AstraZeneca AB (SE) 2011-01-12 EP disclosed
WO-2009130496-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-29 WO disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 CYP2S1, HSD11B1, HSD3B1 TYRO3 4281/4885SELP 3995/4885CHEK1 3919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.